Posted by Michael Wonder on 08 Apr 2025
AbbVie announces European Commission approval of Rinvoq (upadacitinib) for the treatment of adults with giant cell arteritis
8 April 2025 - This marks the eighth approved indication for Rinvoq in the EU.
AbbVie today announced that the European Commission granted marketing authorisation to Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis in adult patients.
